Drug intelligence / Profile preview

TA103

Development stage: Phase 1

Overview

TA103 is an investigational drug evaluated in a multi-center, double-blind, randomized, placebo-controlled clinical trial for the treatment of tinea pedis (athlete's foot). The specific mechanism of action, chemical class, and developer information are not publicly disclosed. The available data indicate that it is being studied as a potential therapy for fungal infections affecting the feet[2].

Beyond the preview

Go deeper on TA103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TA103.

Explore the full profile